Opinion of the Transparency Council – quetiapinum

At its Meeting on 23 May 2022, the Transparency Council adopted Opinion No. 84/2022 on reimbursement of medicines containing the active substance quetiapinum for indications for use or posology or route of administration different from those specified in the Summary of Product Characteristics, i.e. for mental disorders other than those listed in the SmPC in patients with dementia.

Publication with the minutes of the Transparency Council meeting